Literature DB >> 11673109

Detection of tumor parenchymal blood flow in hepatic tumors: value of second harmonic imaging with a galactose-based contrast agent.

Hong Ding1, Masatoshi Kudo, Kiyoshi Maekawa, Yoichirou Suetomi, Yasunori Minami, Hirokazu Onda.   

Abstract

Purpose. To evaluate the detectability of tumor vascularity in hepatic tumors by second harmonic imaging with the administration of a microbubble contrast agent, Levovist. Materials and methods: Twenty-four patients with hepatic tumors (21 hepatocellular carcinoma, one focal nodular hyperplasia and two liver metastasis) were studied using Aloka SSD 5500 with the administration of Levovist. Intermittent harmonic gray-scale imaging (HGSI) and intermittent harmonic power Doppler imaging (HPDI) were performed on every tumor and the detectability of the two harmonic imaging modes were compared with that of dynamic CT.
Results: Tumor vessels and tumor parenchymal blood flow were obtained in hypervascular tumors in the early arterial phase, and metastasis presented peripheral enhancement. When dynamic CT was taken as a gold standard, the sensitivity, specificity and accuracy of detecting tumor vascularity for intermittent HGSI were 55.6, 100 and 66.7%, and for intermittent HPDI were 83.3, 100 and 87.5%, respectively. The difference of detectability between the two modes was statistically significant (P<0.05). Depth of the lesion from the abdominal wall was a major factor affecting the detectability of tumor vascularity.
Conclusion: With the administration of Levovist, intermittent HPDI was more sensitive than intermittent HGSI to demonstrate tumor vessels and tumor blood flow. Second harmonic imaging with Levovist would be a promising valuable means for investigating specific vascular features in hepatic tumors.

Entities:  

Year:  2001        PMID: 11673109     DOI: 10.1016/s1386-6346(01)00106-1

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

1.  Radiofrequency ablation of hepatocellular carcinoma: Current status.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  World J Radiol       Date:  2010-11-28

2.  Hepatic malignancies: Correlation between sonographic findings and pathological features.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  World J Radiol       Date:  2010-07-28

3.  Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  World J Radiol       Date:  2009-12-31

4.  Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT.

Authors:  M Mandai; M Koda; T Matono; T Nagahara; T Sugihara; M Ueki; K Ohyama; Y Murawaki
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

5.  Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound: comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound.

Authors:  Masahiko Koda; Yoshiko Matsunaga; Masaru Ueki; Yoshiko Maeda; Ken-ichi Mimura; Kinya Okamoto; Keiko Hosho; Yoshikazu Murawaki
Journal:  Eur Radiol       Date:  2003-12-16       Impact factor: 5.315

6.  Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography.

Authors:  M Kitano; M Kudo; K Maekawa; Y Suetomi; H Sakamoto; N Fukuta; R Nakaoka; T Kawasaki
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.